Literature DB >> 26121095

Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs.

Lauren A Canary, R Monina Klevens, Scott D Holmberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26121095     DOI： 10.7326/M15-0320

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  55 in total

1.  Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals.

Authors:  Sumeyye Samur; Brian Kues; Turgay Ayer; Mark S Roberts; Fasiha Kanwal; Chin Hur; Drew Michael S Donnell; Raymond T Chung; Jagpreet Chhatwal
Journal:  Clin Gastroenterol Hepatol       Date:  2017-06-17       Impact factor: 11.382

2.  Toward a more accurate estimate of the prevalence of hepatitis C in the United States.

Authors:  Brian R Edlin; Benjamin J Eckhardt; Marla A Shu; Scott D Holmberg; Tracy Swan
Journal:  Hepatology       Date:  2015-08-25       Impact factor: 17.425

3.  Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C.

Authors:  Kohtaro Ooka; James J Connolly; Joseph K Lim
Journal:  Am J Gastroenterol       Date:  2017-04-04       Impact factor: 10.864

4.  Health Insurance and Coverage of Evidence-Based Care.

Authors:  Sara Rosenbaum
Journal:  Public Health Rep       Date:  2017-01-30       Impact factor: 2.792

5.  Hepatitis C Management Simplification From Test to Cure: A Framework for Primary Care Providers.

Authors:  Shashi N Kapadia; Kristen M Marks
Journal:  Clin Ther       Date:  2018-07-05       Impact factor: 3.393

6.  Racial-Ethnic Disparities in Uptake of New Hepatitis C Drugs in Medicare.

Authors:  Jeah Jung; Roger Feldman
Journal:  J Racial Ethn Health Disparities       Date:  2016-12-07

Review 7.  Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.

Authors:  Bassem Matta; Tzu-Hao Lee; Keyur Patel
Journal:  Curr HIV/AIDS Rep       Date:  2016-10       Impact factor: 5.071

8.  Fibrosis Progression in Patients With Chronic Hepatitis C Virus Infection.

Authors:  Marija Zeremski; Rositsa B Dimova; Jaroslaw Pillardy; Ype P de Jong; Ira M Jacobson; Andrew H Talal
Journal:  J Infect Dis       Date:  2016-08-02       Impact factor: 5.226

9.  Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population.

Authors:  Julia L Marcus; Leo B Hurley; Scott Chamberland; Jamila H Champsi; Laura C Gittleman; Daniel G Korn; Jennifer B Lai; Jennifer O Lam; Mary Pat Pauly; Charles P Quesenberry; Joanna Ready; Varun Saxena; Suk I Seo; David J Witt; Michael J Silverberg
Journal:  Public Health Rep       Date:  2018-05-11       Impact factor: 2.792

10.  Missed opportunities for prevention and treatment of hepatitis C among persons with HIV/HCV coinfection.

Authors:  Alexander J Millman; Qingwei Luo; Noele P Nelson; Claudia Vellozzi; John Weiser
Journal:  AIDS Care       Date:  2019-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.